MedTrace Logo

Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis

NCT00534313 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2012-08-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.

Conditions

Interventions

DRUG

Abatacept

Solution, intravenous, monthly, short-term = 24 weeks (6 months)

DRUG

Placebo

Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-12-31
Completion
2011-05-31

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Canada
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • South Africa
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00534313 on ClinicalTrials.gov